ArticleNature structural & molecular biology2010
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies.
Article in Nature structural & molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.PLoS pathogens · 2012Trial
- Cloning, expression and characterisation of antigen-specific recombinant bat immunoglobulin from the black flying fox (Frontiers in immunology · 2026Article
- Prediction of pre- and postfusion conformations of class I fusion proteins with AlphaFold2.PloS one · 2026Article
- A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus.PLoS pathogens · 2025Article
- Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- HIV-1 Vpu restricts Fc-mediated effector functions in vivo.Cell reports · 2022Article
- The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.International journal of molecular sciences · 2022Article
- Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.Frontiers in immunology · 2022Article
- A platform technology for generating subunit vaccines against diverse viral pathogens.Frontiers in immunology · 2022Article
- Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.NPJ vaccines · 2021Article
- Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.Viruses · 2021Article
- Potential neutralizing antibodies discovered for novel corona virus using machine learning.Scientific reports · 2021Article
- Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.Clinical & translational immunology · 2021Article
- A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2.Molecules (Basel, Switzerland) · 2020Article
- Selection and immune recognition of HIV-1 MPER mimotopes.Virology · 2020Article
- Distinct conformational states of SARS-CoV-2 spike protein.Science (New York, N.Y.) · 2020Article
- HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes.Nature chemical biology · 2020Article
- Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies.Molecular therapy. Methods & clinical development · 2019Article
- Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions.Nature communications · 2019Article
- Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.Journal of immunology research · 2019Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
HIV-1 envelope glycoprotein gp41 undergoes large conformational changes to drive fusion of viral and target cell membranes, adopting at least three distinct conformations during the viral entry process. Neutralizing antibodies against gp41 block HIV-1 infection by targeting gp41's membrane-proximal external region in a fusion-intermediate state. Here we report biochemical and structural evidence that non-neutralizing antibodies, capable of binding with high affinity to an immunodominant segment adjacent to the neutralizing epitopes in the membrane-proximal region, recognize a gp41 conformation that exists only when membrane fusion is complete. We propose that these non-neutralizing antibodies are induced in HIV-1-infected individuals by gp41 in a triggered, postfusion form and contribute to production of ineffective humoral responses. These results have important implications for gp41-based vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.